Table 1 Non-canonical regions confirmed in the second validation GWAS and four canonical regions for comparison
Locus/site | Drug | AF | Scaled effect size | Scaled SE | P value raw | Drug | AF | OR | SE | P value raw |
---|---|---|---|---|---|---|---|---|---|---|
ubiA (Rv3806c) | EMB, INH, RIF, PZA, KAN | 0.071 | 0.52 | 0.07 | 1E-13 | EMB, INH, RIF, PZA | 0.066 | 1.25 | 0.10 | 3.6E-03 |
Rv3805c - 4267647 T > C (D397G) | AMI | 0.050 | 2.72 | 0.63 | 4E-06 | AMI | 0.283 | 1.11 | 0.03 | 4.7E-04 |
dinG† | RIF | 0.069 | 1.86 | 0.47 | 2E-05 | AMI, STR | 0.293 | 1.10 | 0.03 | 8.8E-04 |
whiB6^ | CAP, AMI, KAN | 0.037 | 0.59 | 0.15 | 3E-05 | CAP, AMI | 0.069 | 1.16 | 0.06 | 2.7E-03 |
RNase J (Rv2752c) | INH, RIF | 0.042 | 0.77 | 0.20 | 8E-05 | KAN, AMI, RIF, INH | 0.067 | 1.29 | 0.06 | 2.8E-08 |
sirA | ETA | 0.070 | 0.78 | 0.21 | 1E-04 | CAP, KAN, STR | 0.015 | 1.27 | 0.09 | 8.0E-04 |
PPE35 | PZA | 0.112 | 0.54 | 0.14 | 1E-04 | EMB | 0.334 | 1.24 | 0.08 | 4.9E-04 |
Rv3434c* | KAN, AMI | 0.048 | 1.14 | 0.33 | 1E-04 | KAN, AMI | 0.047 | 1.18 | 0.06 | 2.3E-03 |
espK-espL | RFB, RIF | 0.053 | 1.21 | 0.34 | 2E-04 | AMI, STR | 0.283 | 1.11 | 0.03 | 4.7E-04 |
Rv2952** | EMB | 0.067 | 0.64 | 0.17 | 2E-04 | STR,AMI INH,CAP | 0.203 | 1.29 | 0.08 | 2.6E-05 |
ccsA | KAN | 0.052 | 1.64 | 0.47 | 3E-04 | AMI, CAP | 0.274 | 1.11 | 0.03 | 2.7E-04 |
thyX-hsdS.1 | AMI | 0.018 | 0.74 | 0.22 | 3E-04 | STR | 0.016 | 1.32 | 0.13 | 3.9E-03 |
kefB (Rv3236c)*** | PZA | 0.137 | 0.80 | 0.24 | 6E-04 | RIF,INH, PZA,EMB STR | 0.235 | 1.60 | 0.16 | 2.0E-06 |
inhA | INH | 0.03 | 1.10 | 0.26 | 2E-05 | – | ||||
Rv1482c-fabG1 | INH | 0.10 | 0.63 | 0.16 | 6E-05 | – | ||||
pncA | PZA | 0.24 | 1.40 | 0.07 | 4E-89 | – | ||||
pncA-Rv2044c | PZA | 0.01 | 0.81 | 0.20 | 7E-5 | – |